100 related articles for article (PubMed ID: 25096460)
21. Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children.
Pawlowska M
Expert Opin Drug Saf; 2015 Mar; 14(3):343-8. PubMed ID: 25599750
[TBL] [Abstract][Full Text] [Related]
22. Treatment rate and factors related to interferon-based treatment initiation for chronic hepatitis C in South Korea.
Lee SS; Jeong SH; Jang ES; Kim YS; Lee YJ; Jung EU; Kim IH; Bae SH; Lee HC
J Med Virol; 2016 Feb; 88(2):275-81. PubMed ID: 26211752
[TBL] [Abstract][Full Text] [Related]
23. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
[TBL] [Abstract][Full Text] [Related]
24. Serum complements C3 and C4 in chronic HCV infection and their correlation with response to pegylated interferon and ribavirin treatment.
El-Fatah Fahmy Hanno A; Mohiedeen KM; Deghedy A; Sayed R
Arab J Gastroenterol; 2014 Jun; 15(2):58-62. PubMed ID: 25097047
[TBL] [Abstract][Full Text] [Related]
25. [Effects of treatment with pegylated interferon and ribavirin in children with chronic hepatitis C].
Kowala-Piaskowska A; Figlerowicz M; Mozer-Lisewska I; Słuzewski W
Przegl Epidemiol; 2005; 59(2):491-8. PubMed ID: 16190558
[TBL] [Abstract][Full Text] [Related]
26. [Chronic hepatitis C virus infection: clinical picture and treatment possibilities].
Annicchiarico BE; Siciliano M; Gasbarrini A
G Ital Nefrol; 2012; 29 Suppl 54():S103-8. PubMed ID: 22388839
[TBL] [Abstract][Full Text] [Related]
27. Endogenous IFNγ in chronic HCV genotype 4 patients treated with PEG-IFNα and ribavirin.
Sadeq R; Mohtady H; Al Badawy N; Ibrahim S; Omar AR; Husseiny MI; El Zowalaty M
J Infect Dev Ctries; 2013 Nov; 7(11):859-67. PubMed ID: 24240045
[TBL] [Abstract][Full Text] [Related]
28. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
Michielsen P; Ho E; Francque S
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
[TBL] [Abstract][Full Text] [Related]
29. Diagnosing and treating hepatitis C virus infection.
Schiff ER
Am J Manag Care; 2011 Mar; 17 Suppl 4():S108-15. PubMed ID: 21767067
[TBL] [Abstract][Full Text] [Related]
30. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
[TBL] [Abstract][Full Text] [Related]
31. Emerging therapies for hepatitis C virus.
Birerdinc A; Younossi ZM
Expert Opin Emerg Drugs; 2010 Dec; 15(4):535-44. PubMed ID: 20629602
[TBL] [Abstract][Full Text] [Related]
32. [Goals of treatment, indication, and treatment for chronic hepatitis C].
Paik SW
Korean J Gastroenterol; 2008 Jun; 51(6):368-71. PubMed ID: 18604138
[TBL] [Abstract][Full Text] [Related]
33. Natural history of hepatitis C and the impact of anti-viral therapy.
Boyer N; Marcellin P
Forum (Genova); 2000; 10(1):4-18. PubMed ID: 10717254
[TBL] [Abstract][Full Text] [Related]
34. Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan.
Lin JA; Chen YC; Cheng SN; Chen PJ; Chu HC; Hsieh TY; Shih YL
J Formos Med Assoc; 2014 Oct; 113(10):727-33. PubMed ID: 24231092
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
Harada N; Hiramatsu N; Oze T; Morishita N; Yamada R; Hikita H; Miyazaki M; Yakushijin T; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
J Viral Hepat; 2014 May; 21(5):357-65. PubMed ID: 24716638
[TBL] [Abstract][Full Text] [Related]
36. [Hepatitis C].
Moradpour D; Blum HE
Ther Umsch; 2004 Aug; 61(8):493-8. PubMed ID: 15457965
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.
Esmat GE; Al Akel W; Abdel Aziz RA; Al Sayed Taha A; Sabry D; Rashed LA; Mostafa A; El Kazaz AY; Ahmed SH
J Interferon Cytokine Res; 2016 Mar; 36(3):149-58. PubMed ID: 26982165
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 6 and 12, alanine aminotransferase activity, and HCV viral load in children with chronic hepatitis C treated with interferon and ribavirin.
Kowala-Piaskowska A; Mozer-Lisewska I; Figlerowicz M; Machowska L; Słuzewski W
Inflammation; 2004 Dec; 28(6):319-25. PubMed ID: 16245074
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis C virus with normal transaminase levels.
Puoti C
Dig Dis; 2007; 25(3):277-8. PubMed ID: 17827956
[TBL] [Abstract][Full Text] [Related]
40. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
